# Interferon beta-1a

## Rebif inj 44mcg

| TAH Drug Code      | [IREB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IREB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | SCï¼Œ initial: 8.8 mcg 3 times weekly on week 1-2.Titration: 22 mcg 3 times weekly on week 3-4.Target dose: 44 mcg 3 times weekly after week 5. target dose may be decreased to 22 mcg if necessary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | >10%: Headache (58% to 70%)ï¼Œ fatigue (33% to 41%)ï¼Œ depression (18% to 25%)ï¼Œ pain (23%)ï¼Œ chills (19%)ï¼Œ dizziness (14%)ï¼Œ Nausea (23%)ï¼Œ abdominal pain (8% to 22%)ï¼Œ Urinary tract infection (17%)ï¼Œ Leukopenia (28% to 36%)ï¼Œ lymphadenopathy (11% to 12%)ï¼Œ Increased serum ALT (20% to 27%)ï¼Œ increased serum AST (10% to 17%)ï¼Œ Antibody development (neutralizing; significance not known; Rebif: 24% to 31%; Avonex: 5%)ï¼Œ Injection site reaction (3% to 92%)ï¼Œ Myalgia (25% to 29%)ï¼Œ back pain (23% to 25%)ï¼Œ weakness (24%)ï¼Œ skeletal pain (10% to 15%)ï¼Œ rigors (6% to 13%)ï¼Œ Visual disturbance (7% to 13%)ï¼Œ Flu-like symptoms (49% to 59%)ï¼Œ sinusitis (14%)ï¼Œ upper respiratory tract infection (14%)ï¼Œ Fever (20% to 28%) 1% to 10%: Chest pain (5% to 8%)ï¼Œ vasodilation (2%)ï¼Œ Hypertonia (6% to 7%)ï¼Œ migraine (5%)ï¼Œ ataxia (4% to 5%)ï¼Œ drowsiness (4% to 5%)ï¼Œ malaise (4% to 5%)ï¼Œ seizure (1% to 5%)ï¼Œ suicidal tendencies (4%) Dermatologic: Erythematous rash (5% to 7%)ï¼Œ maculopapular rash (4% to 5%)ï¼Œ alopecia (4%)ï¼Œ hyperhidrosis (4%)ï¼Œ urticariaï¼Œ Thyroid disease (4% to 6%)ï¼Œ Xerostomia (1% to 5%)ï¼Œ toothache (3%)ï¼Œ Urinary frequency (2% to 7%)ï¼Œ urinary incontinence (2% to 4%)ï¼Œ urine abnormality (3%)ï¼Œ Thrombocytopenia (2% to 8%)ï¼Œ anemia (3% to 5%)ï¼Œ Hyperbilirubinemia (2% to 3%)ï¼Œ Infection (7%)ï¼Œ Pain at injection site (8%)ï¼Œ bruising at injection site (6%)ï¼Œ inflammation at injection site (6%)ï¼Œ tissue necrosis at injection site (1% to 3%)ï¼Œ Arthralgia (9%)ï¼Œ Eye disease (4%)ï¼Œ xerophthalmia (1% to 3%)ï¼Œ Bronchitis (8%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/interferon-beta-1a-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

